XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheet Details
 3 Months Ended
Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Balance Sheet Details

5. Balance Sheet Details

Inventory consisted of the following (in thousands):

 

 

 

March 31,
2022

 

 

December 31,
2021

 

Finished goods

 

$

1,728

 

 

$

1,114

 

Work in process

 

 

5,281

 

 

 

6,767

 

Raw material

 

 

6,205

 

 

 

6,217

 

 

 

$

13,214

 

 

$

14,098

 

Reported as:

 

 

 

 

 

 

    Inventory

 

$

7,009

 

 

$

7,881

 

    Long-term inventory

 

 

6,205

 

 

 

6,217

 

    Total

 

$

13,214

 

 

$

14,098

 

Amount reported as long-term inventory consisted of raw materials as of March 31, 2022 and December 31, 2021. The Company has raw materials beyond one year production plan that help limit the exposures from potential supply interruption. Those raw materials that beyond one year production plan were classified as long-term inventory.

Accrued liabilities consisted of the following (in thousands):

 

 

 

March 31,
2022

 

 

December 31,
2021

 

Accrued sales allowances

 

$

31,497

 

 

$

15,717

 

Accrued research and development services

 

 

29,918

 

 

 

27,270

 

Accrued compensation and benefits

 

 

21,645

 

 

 

25,896

 

Current portion of lease liabilities

 

 

8,944

 

 

 

8,304

 

Accrued consulting and professional fees

 

 

8,641

 

 

 

9,319

 

Current portion of accrued branded prescription drug fees

 

 

7,021

 

 

 

1,959

 

Other

 

 

1,169

 

 

 

727

 

 

 

$

108,835

 

 

$

89,192